1011-16-1

Basic information

• Product Name: N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE
• Synonyms: 1-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE;1-(2-FLUOROPHENYL)PIPERAZINE MONOHYDROCHLORIDE;LABOTEST-BB LT00160127;N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE;TIMTEC-BB SBB003382;1-(2-trifluoromethylphenyl)piperazineHCl;1-(2-Fluorophenyl)piperazine monohydrochloride,98%;1-(2-fluorophenyl)piperazine DIHCL
• CAS NO: 1011-16-1
• Molecular Formula: C₁₀H₁₃FN₂*ClH
• Molecular Weight: 216.68
• EINECS: 1533716-785-6
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 1011-16-1.mol

Chemical Properties

• Melting Point: 187-189 °C(lit.)
• Boiling Point: 283.8 °C at 760 mmHg
• Flash Point: 125.4 °C
• Appearance: white to off-white crystalline powder
• Vapor Pressure: 0.0031mmHg at 25°C
• CAS DataBase Reference: N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE(1011-16-1)
• EPA Substance Registry System: N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE(1011-16-1)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 1011-16-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE is used as a key intermediate in the synthesis of new piperazine derivatives for the development of innovative pharmaceuticals. Its application in this industry is driven by the need to create novel compounds with improved therapeutic properties and reduced side effects.
Used in Research and Development:
In the field of research and development, N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE serves as a valuable compound for conducting pharmacological studies. These studies aim to understand the compound's interactions with biological systems, its potential therapeutic effects, and its safety profile. This knowledge is crucial for the development of new drugs with better efficacy and safety profiles.
Used in Drug Synthesis:
N-(2-FLUOROPHENYL)PIPERAZINE HYDROCHLORIDE is also used as a starting material in the synthesis of various piperazine-based drugs. Its unique chemical properties make it an attractive candidate for the development of new medications with diverse applications, such as antidepressants, antipsychotics, and antihistamines.

InChI:InChI=1/C10H13FN2.ClH/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13;/h1-4,12H,5-8H2;1H

Upstream product

• 348-54-9 2-Fluoroaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 101413-03-0 2-{2-[4-(2-Fluoro-phenyl)-piperazin-1-yl]-ethyl}-1,2,3,4,6,7,8,9-octahydro-benzo[b][1,6]naphthyridine 
• 191591-95-4 5-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-1-methyl-1,4,5,6,7,8-hexahydropyrrolo-[3,2-c]azepine-4,8-dione 
• 101413-07-4 2-{2-[4-(2-Fluoro-phenyl)-piperazin-1-yl]-ethyl}-1,2,3,4,6,7,8,9-octahydro-benzo[b][1,6]naphthyridine; compound with (E)-but-2-enedioic acid 
• 211304-22-2 1-(3-Methyl-4-benzyloxynaphthoxy)-3-[4-(2-fluorophenyl)-1-piperazinyl] propan-2-ol hydrochloride 
• 170631-33-1 2-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]-3,4-dihydro-2H-1,2-benzothiazin-4-one 1,1-dioxide ethylene acetal 
• 178672-13-4 2-{3-[4-(2-fluorophenyl)piperazin-1-yl]propyl}-1H-isoindole-1,3(2H)-dione 
• 1361118-53-7 4-(2-fluorophenyl)piperazine-1-carboximidamide hydrochloride 

Relevant articles and documents

Exploration of substituted arylpiperazine–tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors

In the search for potent dual norepinephrine and dopamine reuptake inhibitors, several substituted arylpiperazine–tetrazoles were designed, synthesized and evaluated for their neurotransmitter reuptake inhibitory activities. Various derivatives exhibited selective and strong neurotransmitter reuptake inhibitory activity. In particular, compounds with a three-carbon linker displayed selective and stronger potency than those with two-carbon and four-carbon linkers. Interestingly, six compounds, 9b, 9c, 9d, 9o, 9q and 9u displayed more effective activity than the standard drug, bupropion. The provided SAR data and potent biological activity can offer useful guidelines for designing dual norepinephrine and dopamine reuptake inhibitors as effective therapeutic agents for treatment of several central nervous system diseases.

Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists

The dopamine D3 receptor (D3R) is a proven therapeutic target for the treatment of neurological and neuropsychiatric disorders. In particular, D3R-selective ligands that can eliminate side effects associated with dopamine D2 receptor (D2R) therapeutics have been validated. However, the high homology in signaling pathways and the sequence similarity between D2R and D3R have rendered the development of D3R-selective ligands challenging. Herein, we designed and synthesized a series of piperazine-phthalimide bitopic ligands based on a fragment-based and molecular docking inspired design. Compound 9i was identified as the most selective D3R ligand among these bitopic ligands. Its selectivity was improved compared to reference compounds 1 and 2 by 9- and 2-fold, respectively, and it was 21-fold more potent than compound 2. Molecular docking demonstrated that the orientation of Leu2.64 and Phe7.39 and the packing at the junction of helices may affect the specificity for D3R over D2R. Functional evaluation revealed that D3R-selective ligand 9i displayed a subpicomolar agonist activity at D3R with a 199-fold increase in potency compared to quinpirole. These results may be useful for the fragment-based design of bitopic compounds as selective D3R ligands.

Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions

A method of treating allergic disorders and pharmaceutical compositions therefore are disclosed for a series of 5-[(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives of Formula I. These compounds are useful in inhibiting Type I allergic STR1 responses in a living animal and thus can be used to treat allergic phenomena such as asthma, rhinitis, atopic dermatitis, chronic hives, allergic conjunctivitis and the like.